Business Wire

Global Processing Services Welcomes Three Independent Non-Executive Directors to Its Board

23.2.2023 08:00:00 EET | Business Wire | Press release

Share

Global Processing Services (“GPS”), a fast-growing next-gen global payments technology platform, today announced the appointment of Paulette Rowe, Shane Happach, and Lynn McCreary as independent Non-Executive Directors.

Paulette Rowe is one of the most influential women in payments, recognised by American Banker in its annual honours list for three consecutive years, and was formerly CEO of Paysafe’s Integrated and Ecommerce Solutions (IES) division. Paulette brings a wealth of experience across card-based and virtual wallet payment solutions. Prior to Paysafe, Paulette was Head of Payments and Financial Services Partnerships for Facebook and held senior roles in a variety of financial organisations over a 20-year period, including Barclaycard, Royal Bank of Scotland (RBS), Tesco Bank, and GE Capital.

Shane Happach is an experienced global payments executive with strengths in enterprise sales and fintech-led disruption. Shane was recently named as CEO of Singapore-based fintech, Coda Payments. Prior to Coda, Shane was CEO of payments fintech Mollie for two years, and spent more than a decade at Worldpay, where he held a number of senior positions, including EVP, Head of Global Ecommerce and Chief Commercial Officer. Before Worldpay, he worked with GlobalCollect – acquired by Ingenico in 2014 – in business development roles across the Americas and EMEA.

Lynn McCreary brings over three decades of experience in legal, business and executive leadership roles to GPS, having worked at financial services and payments firm Fiserv for 11 years, serving as Chief Legal Officer since 2013. Her responsibilities at Fiserv included directing the firm’s global legal, ethical and compliance activities, as well as taking an active role in coordinating its M&A strategy. Prior to joining Fiserv, Lynn was an equity partner at Bryan Cave LLP, now Bryan Cave Lighton Paisner, where she represented the interests of financial services companies, insurance companies, retailers and others in a broad range of commercial disputes. Lynn is currently Chief Legal Officer of Sportradar.

“Paulette, Shane and Lynn bring a wealth of experience to our Board and will support our team to capitalise on the enormous potential for disruption in the issuer processing space,” said Gene Lockhart, Chair of GPS. “GPS is committed to investing for the long-term to support our clients in accelerating innovation, diversifying product capabilities and facilitating new payments programmes worldwide.”

GPS has attracted a number of highly experienced global payments executives under the leadership of Kevin Schultz as Chief Executive Officer since July 2022. The company most recently announced the appointment of Visa veteran Jim McCarthy as Executive Vice President – Global Product and Sales, who has more than 30 years of payments experience; Kevin Fox as Chief Revenue Officer, and Jeff Burns as Chief Financial Officer.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Louisa Bartoszek
Head of Communications, GPS
Louisa.bartoszek@globalprocessing.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release

Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne

U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P

Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof

Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release

Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons

Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release

Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye